These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12438288)

  • 1. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans.
    Virmani R; Liistro F; Stankovic G; Di Mario C; Montorfano M; Farb A; Kolodgie FD; Colombo A
    Circulation; 2002 Nov; 106(21):2649-51. PubMed ID: 12438288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome.
    Liistro F; Stankovic G; Di Mario C; Takagi T; Chieffo A; Moshiri S; Montorfano M; Carlino M; Briguori C; Pagnotta P; Albiero R; Corvaja N; Colombo A
    Circulation; 2002 Apr; 105(16):1883-6. PubMed ID: 11997271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE).
    Kataoka T; Grube E; Honda Y; Morino Y; Hur SH; Bonneau HN; Colombo A; Di Mario C; Guagliumi G; Hauptmann KE; Pitney MR; Lansky AJ; Stertzer SH; Yock PG; Fitzgerald PJ
    Circulation; 2002 Oct; 106(14):1788-93. PubMed ID: 12356631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophilic infiltration in restenotic tissue following coronary stent implantation.
    Rittersma SZ; Meuwissen M; van der Loos CM; Koch KT; de Winter RJ; Piek JJ; van der Wal AC
    Atherosclerosis; 2006 Jan; 184(1):157-62. PubMed ID: 15950231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
    Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A
    Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation.
    Tanabe K; Serruys PW; Grube E; Smits PC; Selbach G; van der Giessen WJ; Staberock M; de Feyter P; Müller R; Regar E; Degertekin M; Ligthart JM; Disco C; Backx B; Russell ME
    Circulation; 2003 Feb; 107(4):559-64. PubMed ID: 12566366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation.
    Yoneda S; Abe S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T
    Coron Artery Dis; 2013 Aug; 24(5):368-73. PubMed ID: 23744617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological features of in-stent restenosis after sirolimus-eluting stent versus bare metal stent placement.
    Abe S; Yoneda S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T
    Cardiovasc Pathol; 2012; 21(2):e19-22. PubMed ID: 21489821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The wound healing response after implantation of a drug-eluting stent is impaired persistently in the long term.
    Nasuno T; Tokura M; Kageyama M; Toyoda S; Sakuma M; Komatsu T; Taguchi I; Abe S; Inoue T
    Heart Vessels; 2016 Jun; 31(6):985-9. PubMed ID: 25939630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial.
    Grube E; Lansky A; Hauptmann KE; Di Mario C; Di Sciascio G; Colombo A; Silber S; Stumpf J; Reifart N; Fajadet J; Marzocchi A; Schofer J; Dumas P; Hoffmann R; Guagliumi G; Pitney M; Russell ME;
    J Am Coll Cardiol; 2004 Oct; 44(7):1368-72. PubMed ID: 15464315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results.
    Strauss BH; Umans VA; van Suylen RJ; de Feyter PJ; Marco J; Robertson GC; Renkin J; Heyndrickx G; Vuzevski VD; Bosman FT
    J Am Coll Cardiol; 1992 Dec; 20(7):1465-73. PubMed ID: 1360479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.
    Kong J; Hou J; Ma L; Xing L; Jia H; Liu H; Zhang S; Yu B; Jang IK
    Arch Cardiovasc Dis; 2013 Feb; 106(2):79-85. PubMed ID: 23527911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment.
    Chung IM; Gold HK; Schwartz SM; Ikari Y; Reidy MA; Wight TN
    J Am Coll Cardiol; 2002 Dec; 40(12):2072-81. PubMed ID: 12505216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-Stent Restenosis with "Inflammatory" Neointima Following Everolimus-Eluting Stent Implantation.
    Tsuji Y; Koide M; Katsura K; Fujita H; Ishibashi-Ueda H; Otsuka F
    Int Heart J; 2018 Sep; 59(5):1142-1145. PubMed ID: 30012926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of everolimus-eluting stent with a bioresorbable polymer coating for treatment of recurrent in-stent restenosis.
    Honda H; Meguro T; Takizawa K; Isoyama S
    J Invasive Cardiol; 2005 Feb; 17(2):112-5. PubMed ID: 15687539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
    Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schömig A; Kastrati A; Mehilli J;
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):161-6. PubMed ID: 21400652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.